EF190

EF190 is a fixed-dose combination (FDC) drug candidate developed by Eurofarma, currently in Phase III clinical development for the treatment of moderate acne vulgaris in women. The formulation consists of a new concentration of cyproterone acetate, a steroidal antiandrogen and progestogen, combined with a reduced dose of ethinylestradiol, a synthetic estrogen. Cyproterone acetate works by competitively inhibiting the androgen receptor, thereby reducing the effects of testosterone and dihydrotestosterone on the sebaceous glands, which decreases sebum production. Ethinylestradiol contributes to the anti-acne effect by suppressing the hypothalamic-pituitary-ovarian axis, leading to reduced ovarian androgen synthesis and an increase in sex hormone-binding globulin (SHBG) levels, which further lowers the concentration of free circulating androgens. This combination is intended to provide a therapeutic benefit for acne while potentially improving the safety profile through the use of a lower estrogen dose compared to traditional formulations.

Other names

cyproterone acetate + ethinylestradiol